Unknown PHASE3 INTERVENTIONAL 1-arm NCT02178683

Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression

Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression After Conditioning With Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor HCT

Sponsor: Colorado Blood Cancer Institute

Conditions Graft Versus Host Disease

Interventions Tacrolimus and MMF.

Updated 6 times since 2017 Last updated: Jun 27, 2014 Started: Nov 30, 2010 Primary completion: Dec 31, 2016 Completion: Dec 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02178683, this PHASE3 trial focuses on Graft Versus Host Disease and remains ongoing. Sponsored by Colorado Blood Cancer Institute, it has been updated 6 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Jan 2019 — Jan 2021 [monthly]

Unknown Status PHASE3

Status: Recruiting → Unknown Status
Jun 2018 — Jan 2019 [monthly]

Recruiting PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE3

First recorded

Nov 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Colorado Blood Cancer Institute

Data source: Colorado Blood Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Denver, United States